• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医用大麻对运动障碍的影响,重点关注亨廷顿病;文献综述。

Medical Marijuana Effects in Movement Disorders, Focus on Huntington Disease; A Literature Review.

机构信息

Saint James School of Medicine.

KEAN University, College of Natural, Applied and Health Sciences, Union, NJ, USA. Saint James School of Medicine, Basic Medical Sciences, Park Ridge, IL USA.

出版信息

J Pharm Pharm Sci. 2020;23. doi: 10.18433/jpps30967.

DOI:10.18433/jpps30967
PMID:33064979
Abstract

PURPOSE

We aimed to comprehensively evaluate the effects of medical marijuana on symptoms that are relevant to movement disorders with a focus on Huntington disease (HD).

METHODS

A systematic review by literature search through PubMed and EBSCO electronic databases was conducted for relevant studies reported after 2002 on the effects of medical marijuana or cannabis use on tremor, spasm, spasticity, chorea, sleep quality and HD-specific rating scales. Study selection, quality assessment and data extraction was performed by three reviewers. Outcome measures were changes in psychomotor, and sleep related symptoms. The methodological quality of the included studies was evaluated. Results: A total of 22 studies were reviewed. There was strong evidence for significant improvement in the neurologic symptoms of spasms, tremors, spasticity, chorea, and quality of sleep following treatment with medical marijuana. Analysis of specific motor symptoms revealed significant improvement after treatment in tremors and rigidity. Furthermore, all pretreatment and post-treatment measures indicated a significant increase in average number of hours slept.

CONCLUSION

Larger scale studies are warranted to test the benefits of medical marijuana in HD patients.  In the meanwhile, clinicians may consider prescribing medical marijuana as part of their strategy for better symptomatic treatment of patients with HD.

摘要

目的

我们旨在全面评估医用大麻对运动障碍相关症状的影响,重点关注亨廷顿病(HD)。

方法

通过 PubMed 和 EBSCO 电子数据库进行系统的文献检索,对 2002 年后报道的关于医用大麻或大麻使用对震颤、痉挛、痉挛、舞蹈病、睡眠质量和 HD 特定评定量表影响的相关研究进行综合评价。由三名评审员进行研究选择、质量评估和数据提取。结果衡量标准为精神运动和睡眠相关症状的变化。评估了纳入研究的方法学质量。

结果

共审查了 22 项研究。有强有力的证据表明,医用大麻治疗可显著改善痉挛、震颤、痉挛、舞蹈病和睡眠质量等神经系统症状。对特定运动症状的分析表明,治疗后震颤和僵直有显著改善。此外,所有治疗前后的测量都表明平均睡眠时间显著增加。

结论

需要更大规模的研究来测试医用大麻在 HD 患者中的益处。与此同时,临床医生可以考虑将医用大麻作为其治疗 HD 患者症状的策略的一部分。

相似文献

1
Medical Marijuana Effects in Movement Disorders, Focus on Huntington Disease; A Literature Review.医用大麻对运动障碍的影响,重点关注亨廷顿病;文献综述。
J Pharm Pharm Sci. 2020;23. doi: 10.18433/jpps30967.
2
Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders [RETIRED]: report of the Guideline Development Subcommittee of the American Academy of Neurology.系统评价:医用大麻在特定神经系统疾病中的疗效与安全性[已停用]:美国神经病学学会指南制定小组委员会报告
Neurology. 2014 Apr 29;82(17):1556-63. doi: 10.1212/WNL.0000000000000363.
3
Medical management of motor manifestations of Huntington disease.亨廷顿病运动表现的医学管理
Handb Clin Neurol. 2017;144:141-150. doi: 10.1016/B978-0-12-801893-4.00012-2.
4
Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.泰必利嗪治疗运动障碍:文献综述。
Clin Ther. 2012 Jul;34(7):1487-504. doi: 10.1016/j.clinthera.2012.06.010. Epub 2012 Jun 28.
5
[Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy].[大麻对多发性硬化症、神经性疼痛患者以及接受化疗的肿瘤患者安全性和治疗效果的系统评价]
Epidemiol Prev. 2017 Sep-Dec;41(5-6):279-293. doi: 10.19191/EP17.5-6.AD01.069.
6
Therapeutic Uses of Cannabis on Sleep Disorders and Related Conditions.大麻在睡眠障碍及相关疾病中的治疗用途。
J Clin Neurophysiol. 2020 Jan;37(1):39-49. doi: 10.1097/WNP.0000000000000617.
7
Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.大麻(医用大麻)治疗帕金森病运动和非运动症状:一项开放标签观察性研究。
Clin Neuropharmacol. 2014 Mar-Apr;37(2):41-4. doi: 10.1097/WNF.0000000000000016.
8
Factors associated with having a medical marijuana card among Veterans with recent substance use in VA outpatient treatment.在退伍军人事务部(VA)门诊治疗中近期有药物使用情况的退伍军人中,与持有医用大麻卡相关的因素。
Addict Behav. 2016 Dec;63:132-6. doi: 10.1016/j.addbeh.2016.07.006. Epub 2016 Jul 8.
9
A single dose of hypnotic corrects sleep and EEG abnormalities in symptomatic Huntington's disease mice.单剂量催眠药可纠正有症状的亨廷顿舞蹈病小鼠的睡眠和脑电图异常。
Neuropharmacology. 2016 Jun;105:298-307. doi: 10.1016/j.neuropharm.2016.01.027. Epub 2016 Jan 22.
10
Documentation of medical marijuana use in cancer patients.癌症患者使用医用大麻的记录。
J Oncol Pharm Pract. 2020 Jul;26(5):1117-1127. doi: 10.1177/1078155219883912. Epub 2019 Nov 10.

引用本文的文献

1
Assessing effects of Cannabis on various neuropathologies: A systematic review.评估大麻对各种神经病理学的影响:一项系统综述。
J Ayurveda Integr Med. 2024 May-Jun;15(3):100911. doi: 10.1016/j.jaim.2024.100911. Epub 2024 Jun 13.
2
Perceived Effectiveness of Medical Cannabis Among Adults with Chronic Pain: Findings from Interview Data in a Three-Month Pilot Study.医用大麻在慢性疼痛成人中的感知有效性:一项为期三个月的试点研究中访谈数据的结果。
Cannabis. 2023 Jul 5;6(2):62-75. doi: 10.26828/cannabis/2023/000149. eCollection 2023.
3
A single-center real-life study on the use of medical cannabis in patients with dystonia.
一项关于肌张力障碍患者使用医用大麻的单中心真实世界研究。
Front Neurol. 2023 Jun 29;14:1218300. doi: 10.3389/fneur.2023.1218300. eCollection 2023.
4
Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty.神经退行性疾病中的内源性大麻素调节:对确定性的追求。
Biology (Basel). 2022 Mar 14;11(3):440. doi: 10.3390/biology11030440.
5
Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination.医用大麻的神经学益处、临床挑战及神经病理学前景:对大麻素在多发性硬化症及脱髓鞘实验模型中作用的系统评价
Biomedicines. 2022 Feb 24;10(3):539. doi: 10.3390/biomedicines10030539.